Testosterone Gel (Testim)

Quick Reference Card

Overview / What Is Testosterone Gel (Testim)?

The Basics

Testim is a prescription testosterone gel designed to replace the testosterone your body can no longer produce in sufficient quantities. Applied once daily to the shoulders and upper arms, it delivers a steady stream of testosterone through your skin and into your bloodstream over 24 hours, mimicking the natural hormone delivery your body provides when functioning normally.

What makes Testim distinct from other testosterone gels on the market is its formulation. The gel uses a unique combination of excipients, including pentadecalactone (a synthetic musk compound), that gives it a characteristic scent and, more importantly from a medical perspective, results in approximately 30% higher bioavailability compared to AndroGel at equivalent doses. In practical terms, this means Testim delivers more testosterone into your bloodstream from the same amount of gel applied to your skin [1].

Testim was originally developed by Auxilium Pharmaceuticals, approved by the FDA in October 2002, and is currently manufactured by DPT Laboratories and distributed by Endo USA, Inc. It is available as a 1% testosterone gel in unit-dose tubes, each containing 50 mg of testosterone in 5 grams of gel. Depending on your response, your provider may prescribe one tube (50 mg) or two tubes (100 mg) per day.

Like all testosterone products, Testim is classified as a Schedule III controlled substance and is available only by prescription. It is specifically indicated for men with diagnosed hypogonadism (either primary or secondary), not for age-related testosterone decline, which remains an off-label use that has not been established as safe and effective in clinical trials.

The Science

Testim (NDA021454) is a clear to translucent hydroalcoholic topical gel containing 1% testosterone (17-beta-hydroxyandrost-4-en-3-one, C19H28O2, MW 288.42). The gel vehicle consists of purified water, pentadecalactone, carbopol, acrylates, propylene glycol, glycerin, polyethylene glycol, ethanol (74%), and tromethamine [1].

FDA approval was granted on October 31, 2002, based on pivotal Phase 3 trials demonstrating that Testim normalized serum testosterone concentrations in hypogonadal men. The initial U.S. approval date for testosterone as a compound is 1953, reflecting its long regulatory history across multiple formulations [1].

A critical pharmacokinetic distinction exists between Testim and other 1% testosterone gels. A two-period, randomized, complete crossover study (n=29) demonstrated that a single 50 mg dose of Testim produced 30% higher total testosterone Cmax and AUC0-24 compared to AndroGel, with free testosterone AUC0-24 approximately 47% higher. Confidence intervals for Cmax and AUC0-24 fell outside bioequivalence limits, establishing that the two formulations are pharmacokinetically distinct [2]. This bioavailability advantage is attributed to differences in the gel excipients, particularly the penetration-enhancing properties of the vehicle components.

The clinical significance of this PK difference was confirmed in a retrospective chart review (n=370): among men switched from AndroGel to Testim due to suboptimal response, mean total testosterone increased from 311 ng/dL to 484 ng/dL (P < 0.001), with the proportion of men remaining below 300 ng/dL dropping from 58% to 17% [3].

Medical / Chemical Identity

Testim does not contain an ester modification. Unlike injectable testosterone formulations (cypionate, enanthate, undecanoate) that require enzymatic ester hydrolysis to release free testosterone, Testim delivers unesterified testosterone directly through the skin. The stratum corneum serves as the depot, providing sustained release over 24 hours following application.

Mechanism of Action / Pathophysiology

The Basics

When you apply Testim to your shoulders and upper arms, the gel dries on your skin within minutes. But beneath the surface, your skin is doing something remarkable: acting like a slow-release reservoir. Testosterone from the gel gradually crosses your outer skin layer and enters the tiny blood vessels in your dermis. From there, it circulates throughout your body, doing exactly what the testosterone your body would make on its own would do.

Once in your bloodstream, testosterone travels to tissues throughout your body and enters cells, where it binds to androgen receptors. These receptors act like molecular switches. When testosterone attaches, it triggers changes in how your cells behave: muscle cells start building more protein, bone cells maintain and strengthen bone structure, brain cells influence mood and cognitive function, and cells in your reproductive system support sexual function. This is why low testosterone can cause such a wide range of symptoms, and why restoring normal levels often improves energy, mood, libido, and body composition simultaneously.

Your body also converts some of the absorbed testosterone into two other important hormones. An enzyme called 5-alpha reductase converts testosterone into dihydrotestosterone (DHT), a more potent androgen that influences hair growth, skin oiliness, and prostate tissue. Another enzyme called aromatase converts some testosterone into estradiol, a form of estrogen that men need in small amounts for bone health, brain function, and cardiovascular protection. The balance between testosterone, DHT, and estradiol is part of what your provider monitors during treatment.

The Science

Testim delivers unesterified testosterone transdermally, bypassing the hepatic first-pass metabolism that limits oral testosterone bioavailability. Following application to the skin, testosterone diffuses through the stratum corneum, which acts as a rate-limiting barrier and reservoir for sustained release into the dermal microcirculation [1].

Once absorbed, free testosterone exerts biological effects through binding to the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The classical genomic pathway involves ligand-AR binding, receptor dimerization, nuclear translocation, and interaction with androgen response elements (AREs) in target gene promoters, modulating transcription over hours to days. Non-genomic signaling through membrane-associated AR activates rapid second messenger cascades (MAPK/ERK, PI3K/Akt, intracellular calcium) within seconds to minutes [4].

Testosterone undergoes two primary metabolic conversions. 5-alpha reductase (types I and II) irreversibly converts testosterone to 5-alpha-dihydrotestosterone (DHT), which has approximately 2-3 times greater AR binding affinity and mediates androgenic effects in skin, hair follicles, and prostate tissue. Aromatase (CYP19A1), expressed predominantly in adipose tissue, brain, and bone, converts testosterone to 17-beta-estradiol (E2). In men, estradiol is essential for bone mineral density maintenance (via ER-alpha-mediated osteoblast regulation), epiphyseal plate closure, negative feedback on GnRH/LH secretion, and neuroprotective functions [4].

Exogenous testosterone administration, regardless of delivery method, suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, reducing GnRH pulse frequency and amplitude, which decreases LH and FSH secretion. This results in reduced intratesticular testosterone concentrations and impaired spermatogenesis, a critical consideration for men of reproductive age [5].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

Understanding how Testim moves through your body helps explain why application technique matters so much. When you squeeze the gel from the tube and rub it onto your shoulders and upper arms, about 10% of the testosterone in the gel actually makes it through your skin and into your bloodstream. That might sound like a small percentage, but the gel is designed with this in mind; each 50 mg tube is calibrated so that the approximately 5 mg that gets absorbed is enough to raise most men's testosterone levels into the normal range.

Your skin acts as a time-release mechanism. After the alcohol in the gel evaporates (which happens within a few minutes), the testosterone forms a thin reservoir in your outer skin layer. From there, it slowly releases into the blood vessels just below the surface over the next 24 hours. This is why you apply the gel daily, and why you should not wash the application area for at least 2 hours after applying.

One important thing to know about Testim specifically: it is not interchangeable with other testosterone gels, even if they contain the same concentration of testosterone. Clinical studies have shown that Testim delivers about 30% more testosterone into the bloodstream than AndroGel at equivalent doses. This means that switching between brands requires medical supervision and retesting of your testosterone levels.

Where you apply the gel also matters. Testim was specifically designed and tested for application to the shoulders and upper arms. Studies have shown that this site provides the highest absorption, followed by the chest/abdomen, with the lowest absorption from the calves/legs. This is likely related to skin thickness and the amount of subcutaneous fat in different body areas.

The Science

Absorption: Testim provides continuous transdermal delivery of testosterone for 24 hours following a single application. Approximately 10% of the applied dose is absorbed into the systemic circulation. The stratum corneum serves as the primary reservoir, with the rate of absorption governed by skin thickness, hydration status, blood flow, and gel vehicle properties [1].

Application site pharmacokinetics: A prospective comparative study (n=21) demonstrated that application site significantly influences absorption. When Testim was applied to three anatomical sites for one month each, total testosterone levels ranked: arms/shoulders > chest/abdomen >= calves/legs (P = 0.011). Calculated free testosterone correlated well with total testosterone across all sites (R2 = 0.87) [6].

Steady-state pharmacokinetics (Day 30 data):

Comparative bioavailability (Testim vs AndroGel, single dose 50 mg):

Distribution: Testosterone is approximately 44% bound to sex hormone-binding globulin (SHBG), 54% bound to albumin, and approximately 2% circulates as free (unbound) testosterone. Free and albumin-bound fractions are considered bioavailable [4].

Metabolism: Testosterone is metabolized to various 17-keto steroids through two primary pathways. 5-alpha reductase converts testosterone to DHT (more potent androgen). Aromatase (CYP19A1) converts testosterone to estradiol. Approximately 90% of a dose is excreted in urine as glucuronic and sulfuric acid conjugates; approximately 6% is excreted in feces [1].

Effect of showering: The application site should not be washed for at least 2 hours after application. Data from testosterone gel studies indicate that showering at 2 or 6 hours post-application has minimal effect on bioavailability. Showering at 10 hours had no effect. The majority of absorption occurs within the first 4 hours [7].

Effect of moisturizer: Application of moisturizing lotion 1 hour after testosterone gel application increased mean Cavg by approximately 14% and Cmax by approximately 17%, suggesting that skin hydration enhances absorption [7].

Understanding how your body absorbs and processes Testim is the foundation for a well-managed protocol. Doserly lets you log every application with timing and dose details, building a clear record of your testosterone protocol over time. Whether you are applying once daily or tracking when you last showered relative to your application, the app helps you maintain the consistency that makes transdermal therapy most effective.

Research & Clinical Evidence

The Basics

Testim has been studied in several clinical trials since its FDA approval in 2002. The key evidence supporting its use comes from both Testim-specific studies and the broader body of research on testosterone replacement therapy in hypogonadal men.

The pivotal Phase 3 trial that led to FDA approval enrolled 304 hypogonadal men treated with Testim 50 mg, Testim 100 mg, or placebo for up to 90 days. The study demonstrated that Testim raised and maintained serum testosterone levels in the normal adult range. Men in the treatment groups experienced improvements in sexual function, mood, and energy compared to placebo.

A larger European multicenter trial (208 men across 29 centers in five countries) compared Testim at two doses to a testosterone patch (Andropatch). Testim outperformed the patch in every measure: testosterone levels, mood scores, body composition, and sexual function. Notably, both Testim doses produced significant improvements in sexual performance, sexual motivation, and spontaneous erections, while the patch produced inconsistent or insignificant improvements. Testim also caused 10 times fewer application-site reactions than the patch.

For broader cardiovascular safety, the most important evidence comes from the TRAVERSE trial, the largest cardiovascular outcome trial in TRT history. While TRAVERSE used a different gel formulation (AndroGel 1.62%), its findings are relevant to all testosterone therapy: the trial found no significant increase in major adverse cardiovascular events (MACE) with testosterone vs placebo in a high-risk population over 33 months.

The Science

Pivotal US Phase 3 Trial (90-day controlled study):
In the controlled clinical study, 304 patients were treated with Testim 50 mg (n=103), Testim 100 mg (n=149), or placebo (n=99). Testim normalized serum testosterone concentrations. Adverse reaction rates were low and comparable to placebo for most endpoints, with hematocrit/hemoglobin increases (1-2% vs 0% placebo) representing the most clinically relevant difference [1].

European Phase 3 Multicenter RCT (McNicholas et al., 2003):
A multicenter randomized controlled trial (n=208, 29 centers across Denmark, Germany, Netherlands, Sweden, and UK) compared Testim 50 mg/day, Testim 100 mg/day, and Andropatch (2 x 2.5 mg patches). Key findings over 90 days:

• Mean testosterone increases from baseline: Testim 100 mg: +12.41 nmol/L; Testim 50 mg: +6.54 nmol/L; Andropatch: +3.82 nmol/L
• Both Testim doses significantly improved positive and negative mood over baseline (P < 0.001); Andropatch did not
• Higher dose Testim produced significant decrease in body fat percentage
• Both Testim doses significantly improved sexual performance, motivation, desire, and spontaneous erections at all sample points
• Testim produced 10-fold fewer application-site reactions than either patch formulation [8]

12-Month Long-Term Data (Bouloux Review, 2005):
A systematic review of five published Testim clinical studies reported that during 12 months of treatment with Testim 50 or 100 mg in 371 hypogonadal men: lean body mass increased significantly (P < 0.001), fat mass decreased by 2.1% (P < 0.001), and bone mineral density increased by 2.58% (P < 0.001) [9].

TRAVERSE Trial (Lincoff et al., 2023):
The TRAVERSE trial (n=5,246, men aged 45-80 with hypogonadism and preexisting or high risk for cardiovascular disease) demonstrated non-inferiority of testosterone gel (1.62%) vs placebo for the primary composite MACE endpoint (death from cardiovascular causes, nonfatal MI, nonfatal stroke) with a hazard ratio of 0.96 (95% CI: 0.78-1.17) over a mean follow-up of 33 months. The upper bound of the 95% CI (1.17) was below the prespecified non-inferiority margin of 1.20. TRAVERSE also noted increased incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group [10].

While TRAVERSE specifically studied AndroGel 1.62%, its findings are considered applicable to testosterone gel therapy broadly, as the cardiovascular risk profile is related to the systemic testosterone exposure rather than the specific gel formulation.

TRiUS Registry (Khera et al., 2011):
The Testim Registry in the United States (TRiUS) was a prospective registry study capturing real-world outcomes of Testim treatment. The registry confirmed improved sexual function with Testim TRT across diverse clinical settings, supporting the clinical trial efficacy findings with real-world evidence [11].

Type 2 Diabetes Study (Magnussen et al., 2023):
A randomized, double-blinded, placebo-controlled 24-week trial in 39 men (50-70 years) with T2D on metformin and low bioavailable testosterone found that Testim treatment increased lean body mass (beta = 1.9 kg, P = 0.001), decreased total fat mass (beta = -1.3 kg, P = 0.009), and reduced hepcidin levels (beta = -9.5 ng/mL, P < 0.001). No dropouts due to adverse effects [12].

Evidence & Effectiveness Matrix

Benefits & Therapeutic Effects

The Basics

For men with genuinely low testosterone levels and symptoms of hypogonadism, Testim can offer meaningful improvements across several areas of health and daily functioning. The most commonly reported benefits include restored sexual desire and function, improved energy and reduced fatigue, better mood stability, and changes in body composition with more muscle and less fat.

Sexual function improvements are often among the first benefits men notice, typically within the first few weeks of treatment. In clinical trials, both Testim doses significantly improved sexual performance, sexual motivation, and desire compared to baseline and compared to testosterone patches. Many men describe this as one of the most immediately noticeable and valued benefits of treatment.

Energy and fatigue improvements tend to follow, with many men reporting that the persistent tiredness and afternoon energy crashes they experienced before treatment begin to resolve. Body composition changes take longer to manifest fully. Over 12 months of treatment, studies show increased lean body mass and decreased fat mass. Bone mineral density improvements have also been documented over this timeframe.

It is important to maintain realistic expectations. Not every symptom will resolve completely, improvements take time (some benefits emerge over months, not weeks), and TRT works best as part of an overall health strategy that includes appropriate exercise, nutrition, and sleep. Additionally, these benefits apply to men with confirmed hypogonadism; the evidence base for testosterone therapy in men with age-related testosterone decline is less robust.

The Science

The therapeutic effects of Testim are supported by multiple clinical trials:

Sexual function: The European Phase 3 RCT demonstrated that both Testim 50 mg and 100 mg significantly improved sexual performance, sexual motivation, sexual desire, and spontaneous erections at all sample points over 90 days compared to baseline (P < 0.001 for each). The patch comparator failed to achieve significance for several sexual function endpoints [8]. The TRiUS registry confirmed these findings in real-world practice [11].

Body composition: In a 12-month study of 371 hypogonadal men, Testim produced statistically significant increases in lean body mass (P < 0.001) and a 2.1% decrease in fat mass (P < 0.001) [9]. In the 24-week T2D study, lean body mass increased by 1.9 kg (P = 0.001) and total fat mass decreased by 1.3 kg (P = 0.009) [12].

Bone health: The Bouloux review reported a 2.58% increase in bone mineral density at 12 months (P < 0.001), consistent with the known role of testosterone (and its aromatization product, estradiol) in maintaining bone density through ER-alpha-mediated osteoblast regulation [9].

Mood: The European Phase 3 RCT demonstrated significant improvements in both positive and negative mood scores with Testim at both doses; the testosterone patch comparator did not achieve significant mood improvement [8].

Transdermal advantage: The steady-state pharmacokinetics of daily gel application produce more stable serum testosterone levels compared to IM injections, which may translate to more consistent mood, energy, and sexual function without the peak-related side effects and trough-related symptom return sometimes seen with injection protocols [4].

Risks, Side Effects & Safety

The Basics

All medications carry risks, and testosterone gel is no exception. Understanding these risks in proper context, with actual numbers rather than vague warnings, helps you and your provider make informed decisions about your care.

The most common side effects seen with Testim in clinical trials were mild: application site reactions (2-4% of users), blood pressure increases (1%), headache (1%), and increases in hematocrit or hemoglobin (1-2%). A distinctive characteristic of Testim is its strong scent, which some men find objectionable, and its tendency to remain sticky on the skin longer than some other gel formulations. In Drugs.com user reviews, about 13% of users specifically cited the odor as a side effect.

The most important safety concern specific to testosterone gels (including Testim) is the risk of transferring testosterone to women or children through skin-to-skin contact with application sites. The FDA requires a boxed warning about this risk. Children who are accidentally exposed can develop signs of early puberty, and pregnant women exposed to testosterone may experience harm to the fetus. Covering application sites with clothing, washing hands thoroughly after application, and washing the application site before skin contact with others are essential precautions.

Regarding cardiovascular safety: the TRAVERSE trial, the largest cardiovascular outcome trial in TRT history, found no significant increase in major adverse cardiovascular events with testosterone gel compared to placebo in high-risk men over 33 months (hazard ratio 0.96, 95% CI: 0.78-1.17). This provides meaningful reassurance, though TRAVERSE also noted increased incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. The 2025 FDA label update for Testim removed the standalone "Cardiovascular Risk" warning section and added updated warnings for venous thromboembolism and blood pressure increases.

For hematocrit, testosterone stimulates red blood cell production, which can raise hematocrit levels above the safe threshold (generally considered >54%). Transdermal testosterone generally produces lower rates of erythrocytosis compared to injections, but monitoring is still required. In the Testim clinical trial, hematocrit/hemoglobin increased in 1-2% of patients at 50-100 mg doses, compared to 0% with placebo.

The Science

Common adverse reactions (Phase 3 controlled trial, n=304):

Cardiovascular safety: The TRAVERSE trial (n=5,246, men aged 45-80 with hypogonadism and cardiovascular risk factors or established CVD) demonstrated non-inferiority of testosterone gel vs placebo for the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke): HR 0.96 (95% CI: 0.78-1.17) over mean follow-up of 33 months. The upper bound (1.17) was below the non-inferiority margin of 1.20. Notably, the testosterone group showed significantly increased incidence of: atrial fibrillation (HR 1.65, P = 0.02), pulmonary embolism (HR 2.57, P = 0.006), and acute kidney injury (HR 1.49, P = 0.009). These findings necessitate continued cardiovascular monitoring during TRT [10].

Polycythemia/erythrocytosis: Testosterone stimulates erythropoiesis through direct stimulation of renal erythropoietin production and reduction of hepcidin. The threshold for clinical concern is hematocrit >54%, at which point dose reduction, route change, or therapeutic phlebotomy should be considered. Transdermal testosterone generally produces lower erythrocytosis rates than IM injections, as the absence of supraphysiological peaks reduces the erythropoietic stimulus. Monitoring should include hematocrit at baseline, 3-6 months, and annually thereafter [5].

Secondary exposure (BOXED WARNING): Virilization has been reported in children secondarily exposed to testosterone gel through skin-to-skin contact with treated men. Reported effects include premature pubic hair development, phallic or clitoral enlargement, increased erections, and aggressive behavior. Strict adherence to transfer precautions is mandatory [1].

Venous thromboembolism (2025 label update): Postmarketing reports of DVT and PE in patients using testosterone products. The 2025 label update added this as a specific warning [1].

Blood pressure (2025 label update): Testim can increase blood pressure, which may increase cardiovascular event risk. Periodic blood pressure monitoring is recommended [1].

Contraindications:

• Known or suspected prostate cancer
• Breast cancer in men
• Women who are pregnant (Category X; testosterone is teratogenic)
• Hematocrit >54% at baseline (relative)
• Uncontrolled heart failure (relative)
• Untreated severe obstructive sleep apnea (relative)

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you are noticing application site irritation, mood changes, blood pressure shifts, or any other concern, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Testim dosing is straightforward compared to some other TRT formulations. The starting dose for most men is 50 mg (one tube) applied once daily. If, after about 14 days, your morning testosterone level is still below the normal range, your provider may increase the dose to 100 mg (two tubes) per day. There is no dose above 100 mg/day studied or recommended for Testim.

The timing matters: applying the gel at roughly the same time each morning helps maintain consistent levels. Morning application also aligns with your body's natural testosterone rhythm, which peaks in the early morning hours.

Before starting Testim, your provider should confirm the diagnosis of hypogonadism by measuring serum testosterone on at least two separate mornings, with both results below the normal range. This two-test requirement exists because testosterone levels can fluctuate day to day and are affected by sleep, stress, illness, and time of day.

One practical distinction between Testim and other gels: Testim comes in individual metal tubes rather than pump dispensers or packets. Each tube contains exactly one 50 mg dose. This fixed-dose packaging makes it easy to know exactly how much you are applying, but also means you cannot easily fine-tune your dose in small increments the way you might with a pump dispenser.

The Science

Prescribing protocol:

1. Confirm hypogonadism: Two morning serum total testosterone measurements below lower limit of normal + consistent signs/symptoms [5]
2. Starting dose: 50 mg/day (one 5 g tube)
3. Initial assessment: Measure morning pre-dose serum testosterone approximately 14 days after initiation
4. Dose adjustment: If pre-dose testosterone is below normal range, increase to 100 mg/day (two tubes)
5. Dose ceiling: 100 mg/day (no clinical data for higher doses)
6. Ongoing monitoring: Testosterone levels, hematocrit, PSA at 3-6 months and annually

Dosing comparison with other transdermal formulations:

Bioavailability note: Due to Testim's approximately 30% higher bioavailability compared to AndroGel at equivalent doses [2], a 50 mg dose of Testim may produce testosterone levels comparable to a higher dose of AndroGel. This is one reason these products are not interchangeable.

Getting the dosing right with Testim often takes a few weeks of monitoring and adjustment. Keeping an accurate record of your daily applications, including timing and number of tubes used, makes this process smoother. Doserly tracks your testosterone gel doses alongside your lab results and symptoms, so your full protocol is always in one place.

The app logs every application with a timestamp and sends reminders when your next dose is due, helping you maintain the daily consistency that makes transdermal therapy most effective and keeps your levels stable.

What to Expect (Timeline)

After starting Testim, here is a general timeline of what many men experience, keeping in mind that individual responses vary considerably:

Days 1-7:

• Gel application becomes part of your morning routine
• Some men notice a subtle energy or mood lift (this may be partly placebo at this early stage)
• The distinctive Testim scent will be noticeable; clothing may stick to application sites
• No significant hormonal changes expected yet (steady state is reached by approximately day 7)

Weeks 2-4:

• Libido changes are often the first noticeable effect for many men
• Energy improvements may begin to emerge
• Your provider should check your testosterone levels around day 14 to assess initial response
• Application site irritation, if it occurs, typically appears in this window
• Possible initial mood shifts, including occasional irritability, as your body adjusts

Months 1-3:

• Sexual function improvements continue to develop
• Energy and mood stabilization become more evident
• Initial body composition changes may begin (subtle at this stage)
• Hematocrit should be checked during this period
• If you tolerate the formulation well, the scent and stickiness become less noticeable as you adapt your routine

Months 3-6:

• Body composition changes become more apparent (reduced fat, increased lean mass) with appropriate exercise
• Strength improvements often noticed in the gym
• Mood and emotional stability typically well-established
• Full sexual function benefits usually realized by this point

Months 6-12:

• Bone mineral density improvements measurable at 12 months (2.58% increase in clinical data)
• Continued body composition improvement
• Full stabilization of most benefits
• Annual monitoring schedule begins (hematocrit, PSA, testosterone levels, lipids)

Ongoing maintenance:

• Daily gel application continues
• Annual comprehensive review with your provider: symptom reassessment, continued indication, risk-benefit discussion, dose optimization
• Regular monitoring of hematocrit (threshold >54%), PSA, and blood pressure

Not every man will experience all of these benefits, and the timeline can vary. Some men respond quickly and dramatically, while others see gradual, incremental improvement. If you have not noticed meaningful improvement after 3-6 months of consistent use at an adequate dose, discuss alternative formulations or delivery methods with your provider.

Fertility Preservation & HPG Axis

Exogenous testosterone, regardless of the delivery method, suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This is one of the most important considerations for any man starting TRT, particularly men of reproductive age who may want biological children in the future.

How TRT affects fertility: When you apply Testim, the absorbed testosterone signals your brain (hypothalamus and pituitary gland) that testosterone levels are adequate, causing it to reduce production of the hormones (GnRH, LH, FSH) that stimulate your testes to produce testosterone and sperm. The result is a dramatic decline in intratesticular testosterone (normally 40-100 times higher than serum levels), which impairs the Sertoli cell function required for spermatogenesis. Approximately 40-60% of men on TRT achieve azoospermia (zero sperm) by 6 months, with most of the remainder showing severe oligospermia (less than 1 million sperm per mL) [5].

This is not a contraceptive method. While TRT dramatically reduces sperm counts, some men retain residual fertility, and TRT should never be relied upon as birth control.

Fertility preservation strategies:

• Sperm banking before TRT: Strongly recommended for men who may want biological children. Bank sperm before initiating any exogenous testosterone therapy.
• HCG co-administration: 250-500 IU subcutaneously 2-3 times weekly during TRT can maintain intratesticular testosterone and support ongoing spermatogenesis. Evidence is supportive but not universally recommended.
• Clomiphene/enclomiphene alternatives: For men who prioritize fertility, selective estrogen receptor modulators (SERMs) can raise endogenous testosterone by stimulating LH/FSH secretion without suppressing spermatogenesis. This is an off-label alternative to exogenous testosterone.

Recovery after discontinuation: If TRT is stopped, HPG axis recovery is possible but variable. The timeline ranges from 6-24+ months, and recovery to pre-TRT testosterone levels is not guaranteed. Factors affecting recovery include duration of TRT use (longer use = slower recovery), age, pre-TRT hormonal status, and whether HCG was used during TRT. Men with primary hypogonadism (testicular failure) have more limited recovery potential than men with secondary hypogonadism (pituitary/hypothalamic dysfunction) [5].

Clinical importance: Fertility counseling should be part of every TRT initiation conversation for men of reproductive age. This applies to Testim just as it applies to injections, patches, or any other form of exogenous testosterone. The delivery method does not meaningfully change the fertility impact.

Interactions & Compatibility

Drug-drug interactions:

• Anticoagulants (warfarin, DOACs): Testosterone may enhance anticoagulant effect. More frequent INR monitoring recommended during TRT initiation and dose changes.
• Insulin and diabetes medications: Androgens may decrease blood glucose, potentially requiring dose reduction of insulin or oral hypoglycemics. The T2D study with Testim showed improved insulin sensitivity [12].
• Corticosteroids: Concurrent use may result in additive fluid retention. Monitor for edema, particularly in patients with cardiac, renal, or hepatic disease.
• 5-alpha reductase inhibitors (finasteride, dutasteride): Block conversion of testosterone to DHT. May reduce androgenic side effects (acne, hair loss, prostate stimulation) but also reduce some DHT-mediated therapeutic effects.
• Aromatase inhibitors (anastrozole): May be co-prescribed to manage elevated estradiol. See Section Section 18 for detailed discussion.
• Opioids: Chronic opioid use suppresses the HPG axis and may be an underlying cause of hypogonadism. Addressing opioid use may reduce the need for TRT.

Supplement interactions:

• DHEA: Additive androgenic effects; may increase estrogen conversion. Use with caution alongside TRT.
• Boron: May increase free testosterone by reducing SHBG. Effect may be additive.
• Zinc: Supports testosterone production; supplementation guide.
• Saw palmetto: Acts as a mild 5-alpha reductase inhibitor; supplementation guide.
• Vitamin D: Associated with testosterone levels; supplementation guide.

Lifestyle factors:

• Alcohol: Suppresses testosterone production and increases aromatase activity (estrogen conversion). Moderate to heavy alcohol use may counteract TRT benefits.
• Sleep: Critical for testosterone production. TRT may worsen obstructive sleep apnea; CPAP optimization recommended.
• Exercise: Resistance training is synergistic with TRT for muscle mass and body composition improvements.
• Body composition: Weight loss in obese men may normalize testosterone levels, potentially reducing the need for TRT.

Related guides:

• Testosterone Gel (AndroGel)
• Testosterone Gel (Fortesta)
• Testosterone Cypionate
• Anastrozole
• HCG
• Clomiphene

Decision-Making Framework

If you are considering testosterone replacement therapy, the decision process involves several important steps:

Diagnosis confirmation: The Endocrine Society requires two morning total testosterone measurements below the lower limit of normal (varies by lab, typically <264-300 ng/dL) plus symptoms consistent with hypogonadism. The AUA uses a 300 ng/dL threshold. These criteria exist to distinguish true hypogonadism from normal daily variation.

When to investigate underlying causes first: Low testosterone can be caused by conditions that are treatable without TRT: obesity (weight loss may normalize testosterone), untreated obstructive sleep apnea (CPAP may improve T levels), chronic opioid use, pituitary pathology, thyroid dysfunction, or depression. Addressing these underlying causes should be considered before committing to lifelong TRT.

FDA-approved vs off-label use: Testim is FDA-approved specifically for men with diagnosed primary or secondary hypogonadism. Use for age-related testosterone decline ("low T clinics") is off-label, and the FDA label explicitly states that safety and efficacy have not been established for this population.

Choosing Testim vs other formulations: Testim may be preferred when higher bioavailability from a topical formulation is desired (30% higher than AndroGel), or when insurance dictates gel brand selection. It may be less preferred by men sensitive to strong fragrances or who find the sticky residue problematic. The choice between gel and injectable formulations involves trade-offs between convenience, cost, stability of levels, and personal preference.

Questions to ask your provider: What are my testosterone levels and do they confirm hypogonadism? Have we ruled out reversible causes? What formulation do you recommend and why? What monitoring schedule will we follow? What are the fertility implications? What will insurance cover?

Finding a qualified provider: Endocrinologists, urologists with andrology interest, and men's health specialists are best positioned to manage TRT. Be cautious of telehealth TRT clinics that prescribe without adequate workup or monitoring.

Administration & Practical Guide

Application steps for Testim:

1. Wash hands with soap and water before handling the tube
2. Open the tube by twisting the cap and squeezing
3. Squeeze the entire contents of the tube into the palm of your hand
4. Apply to clean, dry, intact skin of the shoulders and/or upper arms
5. Limit application area to what will be covered by a short sleeve t-shirt
6. Rub the gel in until it begins to dry (approximately 30 seconds)
7. Wash hands thoroughly with soap and water after application
8. Allow to dry before putting on clothing (some stickiness may persist)
9. Do not shower, swim, or bathe for at least 2 hours after application

Do NOT apply to: Genitals, abdomen, chest, legs, or any other body area. The shoulders and upper arms provide the highest absorption for Testim specifically.

Transfer precautions (CRITICAL):

• Cover application sites with clothing after the gel has dried
• Wash the application site with soap and water before any anticipated skin-to-skin contact
• Women and children should avoid contact with unwashed application sites
• If transfer occurs, the exposed person should wash the area immediately with soap and water

Practical tips from clinical experience:

• Consider wearing latex or nitrile exam gloves during application to avoid hand contamination
• Apply cornstarch or unscented baby powder over dried gel to reduce stickiness
• The scent (pentadecalactone) is most noticeable immediately after application; many users report it becomes less detectable after drying
• The metal tube design can make it difficult to fully empty; fold the tube from the bottom to maximize use
• Morning application is recommended for consistency with natural diurnal testosterone rhythm
• If you forget a dose, apply it as soon as you remember; do not double the next dose
• Store at room temperature (59-86 degrees F / 15-30 degrees C)
• Testim is flammable (74% ethanol content); keep away from open flame until dry

Monitoring & Lab Work

Pre-TRT baseline labs:

• Total testosterone (two morning draws, fasting preferred)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to distinguish primary vs secondary hypogonadism)
• Estradiol (sensitive assay)
• SHBG
• Prolactin (if secondary hypogonadism suspected)
• CBC with hematocrit
• PSA (age-appropriate)
• Lipid panel
• Comprehensive metabolic panel
• DEXA if osteoporosis risk factors present

Initial follow-up (2-4 weeks):

• Morning pre-dose serum testosterone level (approximately 14 days after initiation per Testim label)
• Symptom assessment
• Side effect evaluation
• Dose adjustment if testosterone remains below normal range

3-6 month follow-up:

• Hematocrit (target: maintain below 54%)
• Testosterone level
• PSA
• Symptom reassessment
• Blood pressure

Ongoing monitoring (annually):

• Hematocrit every 6-12 months
• PSA per age-appropriate screening guidelines
• Testosterone levels (for transdermal, any-time-of-day measurement acceptable after steady state)
• Estradiol only if symptomatic (not routine per guidelines)
• Lipid panel annually
• Bone density (DEXA) if osteoporosis was an indication
• Annual review: continued indication, risk-benefit assessment, dose optimization

Estrogen Management on TRT

Testosterone is converted to estradiol by the aromatase enzyme, primarily in adipose tissue. This is a normal physiological process. Estradiol is essential for bone health, cardiovascular health, libido, and cognitive function in men.

When estrogen management matters: Only when clinical symptoms suggest elevated or suppressed estrogen, not based on lab numbers alone. Routine aromatase inhibitor use is NOT recommended by the Endocrine Society or AUA guidelines.

Transdermal testosterone and estrogen: Testosterone gel formulations generally produce lower peak testosterone levels compared to IM injections, which may result in less aromatization and lower E2 fluctuations. However, individual variability is significant, and some men on gel therapy may still experience estrogen-related symptoms.

High E2 symptoms: Gynecomastia (breast tissue growth), excessive fluid retention, emotional lability, nipple sensitivity.
Low E2 symptoms: Joint pain/stiffness, low libido (paradoxically), dry skin, fatigue, depression, bone density loss.

Aromatase inhibitor use (if clinically indicated): Anastrozole 0.25-0.5 mg 2-3 times weekly is the most commonly used AI. Present as a tool for specific clinical situations, not routine co-prescription. Aggressive E2 suppression has documented harms. See Anastrozole guide for detailed coverage.

DIM and natural approaches: Some men use diindolylmethane (DIM) as a mild estrogen modulator. Evidence is limited. See DIM supplement guide for details.

Stopping TRT / Post-Cycle Considerations

HPG axis recovery: When exogenous testosterone is discontinued, the HPG axis (which has been suppressed by the exogenous hormone) must recover. LH and FSH remain suppressed for weeks to months after stopping. Endogenous testosterone production may take 6-24+ months to return, and recovery to pre-TRT levels is not guaranteed.

PCT protocols (community-derived, limited formal study):

• HCG taper: 1000-2000 IU every other day for 2-4 weeks, then taper
• Clomiphene citrate: 25-50 mg daily for 4-8 weeks to stimulate LH/FSH
• Enclomiphene: Newer SERM, may have fewer side effects than clomiphene
• Note: These protocols are adapted from anabolic steroid community practices and are not standardized in clinical guidelines for TRT discontinuation.

Primary vs secondary hypogonadism recovery: Men with primary hypogonadism (testicular failure) have limited capacity for endogenous testosterone recovery regardless of PCT. Men with secondary hypogonadism (pituitary/hypothalamic dysfunction), particularly those whose hypogonadism was caused by reversible factors (obesity, opioids, sleep apnea), may have better recovery prognosis.

Is TRT lifelong? For many men with primary hypogonadism, yes. For others, the answer depends on underlying cause, response to addressing reversible factors, and individual circumstances. This should be discussed with your provider before starting TRT.

Symptoms during recovery: Expect return of hypogonadal symptoms (fatigue, low libido, mood changes) during the recovery period. SERMs can help bridge the gap. Exercise, sleep optimization, and stress management are supportive.

See Stopping TRT & Post-Cycle Recovery for comprehensive coverage.

Special Populations & Situations

Obese Men

Weight loss alone may normalize testosterone levels in some obese men. Consider lifestyle intervention before committing to lifelong TRT. If TRT is initiated in obese men, higher aromatase activity in adipose tissue may increase estradiol conversion. Metabolic benefits of TRT (improved insulin sensitivity, body composition) are documented in obese hypogonadal men, particularly those with T2D [12].

Men with Sleep Apnea

TRT may exacerbate obstructive sleep apnea. CPAP optimization before and during TRT is recommended. Sleep apnea itself can suppress testosterone; treating the sleep apnea may improve testosterone levels without TRT.

Men with Prostate Cancer History

Historically an absolute contraindication. The saturation model suggests that exogenous testosterone may not further stimulate prostate tissue at physiological concentrations, as androgen receptors are already saturated at normal testosterone levels. Active surveillance patients are being studied. This remains controversial and requires specialized urological consultation.

Cardiovascular Disease History

TRAVERSE trial provides reassurance of non-inferiority for MACE in high-risk men. However, TRAVERSE also showed increased atrial fibrillation, PE, and AKI risk. Transdermal testosterone may be preferred over IM in cardiovascular patients due to lower hematocrit elevation and more stable levels.

Type 2 Diabetes

TRT with Testim improved body composition and reduced hepcidin in hypogonadal T2D men in a controlled trial [12]. May improve insulin sensitivity, potentially requiring diabetes medication dose adjustment.

Older Men (>65)

Distinguish age-related decline from true hypogonadism. TRAVERSE and TTrials data come primarily from this population. Lower starting doses often appropriate. Increased polycythemia risk warrants closer monitoring.

Transgender Men (FTM)

Different dosing goals (masculinizing doses) from hypogonadal replacement. Some FTM individuals use Testim for testosterone therapy. Fertility counseling (oocyte preservation) is critical before initiation. Voice changes are permanent. Application site and dosing may differ from hypogonadal male protocols.

Regulatory, Insurance & International

United States (FDA/DEA):

• FDA-approved for primary and hypogonadotropic hypogonadism (NDA021454)
• DEA Schedule III controlled substance
• Generic testosterone gel 1% (Testim equivalent) is available
• Insurance coverage varies; prior authorization often required. Some insurance plans specifically cover or exclude Testim vs AndroGel
• 2025 label update: VTE warning added, blood pressure warning updated, cardiovascular risk section removed

International availability:

• Testim is primarily marketed in the United States
• In the UK and EU, similar 1% testosterone gel formulations are available under different brand names (Testogel, Tostran)
• Schedule/classification varies by country but testosterone is controlled in most jurisdictions

Cost considerations:

• Brand Testim is generally comparable in cost to brand AndroGel
• Generic testosterone gel 1% is available at lower cost
• GoodRx and manufacturer coupons may reduce out-of-pocket costs
• Compounded testosterone cream from specialty pharmacies is often significantly less expensive

Travel with testosterone:

• Carry original prescription packaging
• Obtain a letter from prescribing provider describing medical necessity
• Research destination country's controlled substance regulations before traveling
• Quantity limitations may apply for international travel

Frequently Asked Questions

Q: How is Testim different from AndroGel?
A: Both are 1% testosterone gels, but they are NOT interchangeable. Testim provides approximately 30% higher bioavailability (more testosterone absorbed through the skin) than AndroGel at equivalent doses, due to differences in the gel formulation. Testim also has a distinctive scent from pentadecalactone, is applied only to shoulders/upper arms (not abdomen), and comes in metal tubes rather than packets or pumps.

Q: Why does Testim smell so strong?
A: The scent comes from pentadecalactone, a synthetic musk compound that is part of the gel vehicle. This ingredient contributes to Testim's enhanced skin penetration properties. The scent is most noticeable immediately after application and diminishes as the gel dries. Individual sensitivity to the scent varies widely.

Q: How long does Testim take to work?
A: Steady-state testosterone levels are typically reached within about 7 days of daily application. Libido improvements may be noticed within 2-4 weeks. Energy and mood improvements typically follow over 1-3 months. Body composition changes require 3-12 months. Your provider should check your testosterone levels about 14 days after starting.

Q: Can I switch from another testosterone gel to Testim?
A: Yes, but this should be done under medical supervision with retesting of testosterone levels, as the formulations are not bioequivalent. Research suggests that men who switch from AndroGel to Testim often see improved testosterone levels. Conversely, some men switch from Testim to AndroGel to avoid the odor or stickiness.

Q: Will Testim affect my fertility?
A: Yes. All forms of exogenous testosterone suppress the HPG axis and can significantly reduce sperm production, potentially causing azoospermia. If you may want biological children in the future, discuss fertility preservation options with your provider before starting TRT. See Section Section 13 for detailed coverage.

Q: Can my partner or children be affected by Testim?
A: Yes. Testosterone can transfer through skin-to-skin contact with application sites. This is a boxed warning. Always cover application sites with clothing, wash hands after applying, and wash the application site before anticipated skin contact with others.

Q: Is Testim safe for my heart?
A: The TRAVERSE trial found no significant increase in major cardiovascular events with testosterone gel vs placebo in high-risk men. However, individual cardiovascular risk depends on many factors. Discuss your specific risk profile with your healthcare provider.

Q: Can I apply Testim to areas other than my shoulders?
A: The FDA-approved application site for Testim is the shoulders and upper arms only. Research shows that arms/shoulders provide the highest absorption. While other sites (chest, abdomen, legs) do result in some absorption, levels are lower and the product has not been FDA-evaluated for these sites. Never apply to the genitals or abdomen.

Q: Does the stickiness go away?
A: Testim tends to remain slightly tacky longer than some other gel formulations. Tips include rubbing the gel in thoroughly until it begins drying, waiting a few minutes before dressing, and applying cornstarch or baby powder after the gel dries. Many users report adapting to the sensation over time.

Q: Is Testim a steroid?
A: Testosterone is technically an anabolic-androgenic steroid. However, TRT at prescribed doses aims to restore testosterone to normal physiological levels, not to achieve the supraphysiological levels associated with steroid abuse. There is a meaningful clinical distinction between hormone replacement therapy and performance-enhancing steroid use.

Myth vs. Fact

Myth: "Testim is just a weaker version of testosterone injections."
Fact: Testim delivers testosterone through a different route (transdermal vs intramuscular) but is not inherently weaker. The key difference is delivery pattern: gel provides steady daily levels while injections produce peaks and troughs. In fact, Testim provides approximately 30% higher bioavailability than AndroGel at equivalent doses, and clinical trials demonstrate comparable therapeutic outcomes to other TRT formulations for sexual function, mood, and body composition [2][8].

Myth: "TRT causes heart attacks."
Fact: The TRAVERSE trial (n=5,246), the largest cardiovascular outcome RCT in TRT history, found no significant increase in major adverse cardiovascular events (MACE) with testosterone gel vs placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months in men with cardiovascular risk factors. Earlier observational studies that raised concerns had significant methodological limitations. TRAVERSE did identify increased risk of atrial fibrillation, pulmonary embolism, and acute kidney injury, warranting continued monitoring [10].

Myth: "TRT causes prostate cancer."
Fact: Current evidence does not support a causal link between TRT at physiological doses and prostate cancer initiation. The saturation model suggests that the androgen receptor is fully saturated at normal testosterone levels, so raising testosterone from low-normal to normal does not further stimulate prostate tissue. PSA monitoring is recommended during TRT, and men with known prostate cancer should not use testosterone, but the fear of TRT causing prostate cancer in healthy men is not supported by the evidence [5].

Myth: "Once you start TRT, you can never stop."
Fact: HPG axis recovery after stopping TRT is possible, though the timeline varies (6-24+ months) and full recovery is not guaranteed. Factors include duration of use, age, and underlying cause of hypogonadism. Men with secondary hypogonadism from reversible causes have better recovery prognosis. For men with primary hypogonadism, TRT is often a lifelong commitment, but this is because the underlying condition is permanent, not because TRT creates dependence.

Myth: "TRT will make you permanently infertile."
Fact: TRT dramatically suppresses sperm production (40-60% of men achieve azoospermia by 6 months), but in most cases, spermatogenesis recovers after discontinuation, though recovery may take 6-24+ months and is not guaranteed for all men. Sperm banking before TRT initiation is strongly recommended for men who may want biological children [5].

Myth: "All testosterone gels are the same."
Fact: Different testosterone gels have distinct pharmacokinetic profiles and are NOT interchangeable. Testim provides approximately 30% higher bioavailability than AndroGel at equivalent doses. Application sites differ between products. Switching between gel brands requires medical supervision and retesting [2][3].

Myth: "Higher testosterone doses are always better."
Fact: Testosterone therapy aims to restore levels to the normal physiological range, not to maximize them. Higher doses increase the risk of side effects (polycythemia, estrogen conversion, acne, mood changes) without proportional therapeutic benefit. The Endocrine Society recommends targeting the mid-normal range [5].

Myth: "All men over 40 need testosterone therapy."
Fact: Age-related testosterone decline is a normal physiological process and is not the same as hypogonadism. Not every man with lower testosterone levels has symptoms, and not every man with symptoms has hypogonadism. Lifestyle factors (weight management, sleep, exercise, stress management) should be optimized before considering TRT. FDA-approved indications are for classical hypogonadism only [5].

Myth: "The smell means Testim is working better."
Fact: The distinctive scent of Testim comes from pentadecalactone, a gel excipient. While the formulation properties (including this compound) contribute to Testim's higher bioavailability, the smell itself is not an indicator of absorption or efficacy. The scent is simply a characteristic of the product formulation.

Sources & References

Clinical Guidelines

[1] TESTIM (testosterone gel) Prescribing Information. Endo USA, Inc. Revised 07/2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f2aae1f-898d-4955-be31-678e0cf85395

[5] Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229

Landmark Trials

[10] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025

Clinical Studies

[2] Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Clin Ther. 2003;25(6):1676-1689. doi:10.1016/S0149-2918(03)80161-8. PMID: 12673669

[3] Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213-218. doi:10.1038/sj.ijir.3901612. PMID: 17898800

[4] Testosterone. StatPearls [Internet]. Sizar O, Leslie SW, Pico J. Androgen Replacement. StatPearls Publishing; 2026. https://www.ncbi.nlm.nih.gov/books/NBK534853/

[6] Porque L, Collins G, Engel J. Absorption of testosterone gel 1% (Testim) from three different application sites. J Sex Med. 2009;7(4 Pt 1):1451-1457. doi:10.1111/j.1743-6109.2009.01355.x. PMID: 19549089

[7] Nelson Vergel. Factors that Can Improve Testosterone Gel Absorption. Community forum. 2019. Based on: AndroGel 1.62% Prescribing Information (showering and moisturizer PK studies).

[8] McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69-74. doi:10.1046/j.1464-410X.2003.04034.x. PMID: 12614254

[9] Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther. 2005;27(3):286-298. doi:10.1016/j.clinthera.2005.03.007. PMID: 15878382

Registry / Real-World Data

[11] Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8(11):3204-3213. doi:10.1111/j.1743-6109.2011.02436.x. PMID: 21883952

[12] Magnussen LV, Jorgensen LH, Glintborg D, Andersen MS. Hepcidin Reduction during Testosterone Therapy in Men with Type 2 Diabetes. Nutrients. 2023;16(1):5. doi:10.3390/nu16010005. PMCID: PMC10740671

Government/Institutional Sources

FDA. TESTIM Label (2025). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021454s036lbl.pdf

Related Guides & Cross-Links

Same Category (Transdermal Testosterone)

• Testosterone Gel (AndroGel)
• Testosterone Gel (Fortesta)
• Testosterone Patch (Androderm)
• Compounded Testosterone Cream

Related Treatment Options (Other Delivery Methods)

• Testosterone Cypionate (Depo-Testosterone)
• Testosterone Enanthate (Delatestryl)
• Testosterone Undecanoate Injectable (Aveed/Nebido)
• Intranasal Testosterone (Natesto)
• Testosterone Gels & Topicals Guide
• Testosterone Injections Guide

Ancillary & Complementary

• Anastrozole (Arimidex)
• HCG
• Clomiphene (Clomid)
• Enclomiphene
• Fertility Preservation on TRT
• Estrogen Management on TRT
• TRT Blood Work Guide
• TRT for Beginners

Complementary Supplements

• Zinc
• Vitamin D
• DIM
• Boron
• Saw Palmetto

Condition & Educational

• Primary Hypogonadism
• Secondary Hypogonadism
• Late-Onset Hypogonadism
• Stopping TRT & Post-Cycle Recovery
• TRT Myths vs Facts
• The TRAVERSE Trial Explained